Source BioScience reports strong Q3

Diagnostics and genetic analysis business Source BioScience said a good performance in the third quarter meant it was on track to meet full year expectations.

The company said the three months to the end of September had been a period of sustained growth and

development with increased revenue in both its LifeSciences and Healthcare divisions.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

The performance was underpinned by growth in the firm's cytology business (which studies cell structure), driven by the adoption of automated imaging for cervical cancer screening.

The LifeSciences division also took increasing market share for DNA sequencing in the UK.

Source said it was in a robust financial position with £2m cash as of September 30th, up from £1.8m at the end of June.

MM